Literature DB >> 15344965

Severe elevations of FK506 blood concentration due to diarrhea in renal transplant recipients.

Koichiro Sato1, Noritoshi Amada, Takaomi Sato, Shunji Miura, Yoichi Ohashi, Satoshi Sekiguchi, Susumu Satomi, Hajime Okazaki.   

Abstract

BACKGROUND: The rate of metabolism in the intestine of oral administered FK506 decreases as FK506 passes on to the lower intestine. In transplant recipients with diarrhea given oral FK506, the main areas for absorption of FK506 shift to the lower intestine, where the ability to metabolize FK506 is weaker. Therefore it is considered likely that when FK506 is administered to recipients with diarrhea, the blood concentration of FK506 will be higher.
MATERIAL AND METHODS: Twenty recipients experiencing episodes of diarrhea were investigated to determine the trough level of FK506 and the time required for the FK506 trough level to return to the level that obtained before diarrhea. AUC0-4h and Cmax of FK506 were investigated in eight recipients. In cases with severe diarrhea, the daily fluctuations of FK506 blood concentration were also investigated. RESULT: The FK506 trough level (p < 0.0001), AUC (p = 0.0173), and Cmax (p = 0.0173) were found to be significantly higher during episodes of diarrhea. In almost all cases, it took between 2 and 4 wk for the elevated FK506 trough level to return to its previous level following a bout of diarrhea. In the daily fluctuations of FK506 concentration, Tmax was prolonged. In some cases, the concentration was highest just before administration of FK506, when it should have been at trough level.
CONCLUSIONS: Diarrhea caused significant elevations of trough level, AUC0-4h and Cmax of FK506, and the prolongation of Tmax in renal transplant recipients administered FK506.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15344965     DOI: 10.1111/j.1399-0012.2004.00232.x

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  7 in total

1.  Multi-organism gastrointestinal polymerase chain reaction positivity among pediatric transplant vs non-transplant populations: A single-center experience.

Authors:  John M Stone; Andrew Savage; Michelle Hudspeth; Katherine Twombley; Nagraj Kasi; Jose Antonio Quiros; Ricardo A Arbizu; Scott Curry
Journal:  Pediatr Transplant       Date:  2020-07-08

2.  Tacrolimus nephrotoxicity: beware of the association of diarrhea, drug interaction and pharmacogenetics.

Authors:  Sandrine Leroy; Arnaud Isapof; Sonia Fargue; May Fakhoury; Albert Bensman; Georges Deschênes; Evelyne Jacqz-Aigrain; Tim Ulinski
Journal:  Pediatr Nephrol       Date:  2010-01-21       Impact factor: 3.714

3.  Clostridium difficile Infection (CDI) in Solid Organ and Hematopoietic Stem Cell Transplant Recipients.

Authors:  Carolyn D Alonso; Mini Kamboj
Journal:  Curr Infect Dis Rep       Date:  2014-08       Impact factor: 3.725

4.  Gut microbiota and tacrolimus dosing in kidney transplantation.

Authors:  John R Lee; Thangamani Muthukumar; Darshana Dadhania; Ying Taur; Robert R Jenq; Nora C Toussaint; Lilan Ling; Eric Pamer; Manikkam Suthanthiran
Journal:  PLoS One       Date:  2015-03-27       Impact factor: 3.240

Review 5.  Influence of tacrolimus metabolism rate on renal function after solid organ transplantation.

Authors:  Gerold Thölking; Hans Ulrich Gerth; Katharina Schuette-Nuetgen; Stefan Reuter
Journal:  World J Transplant       Date:  2017-02-24

Review 6.  Inflammation is a major regulator of drug metabolizing enzymes and transporters: Consequences for the personalization of drug treatment.

Authors:  Françoise Stanke-Labesque; Elodie Gautier-Veyret; Stephanie Chhun; Romain Guilhaumou
Journal:  Pharmacol Ther       Date:  2020-07-11       Impact factor: 12.310

7.  Clinically useful limited sampling strategy to estimate area under the concentration-time curve of once-daily tacrolimus in adult Japanese kidney transplant recipients.

Authors:  Ryuto Nakazawa; Miki Yoshiike; Shiari Nozawa; Koichiro Aida; Yuichi Katsuoka; Eisuke Fujimoto; Masahiko Yazawa; Eiji Kikuchi; Yugo Shibagaki; Hideo Sasaki
Journal:  PLoS One       Date:  2019-12-11       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.